Skip to main content
Premium Trial:

Request an Annual Quote

PPD Shutters Menlo Park Facility; SurroMed, in Expanded Deal, Will Relocate There

This article has been updated to include previously unreported news about PPD's restructuring plan.


NEW YORK, July 17 - PPD has shuttered its functional genomics facility Menlo Park, Calif., as the company undergoes a broad restructuring, PPD said yesterday.


PPD also said it will consolidate its discovery sciences muscle in Morrisville, NC, and Middletown, Wis., "to streamline its chemistry and preclinical resources for lead optimization," PPD said in a statement.


"These strategic decisions better align our company with market drivers," PPD CEO Fred Eshelman said in the statement. "By priming drug candidates for development, lead optimization allows us to provide our clients an integrated portfolio of services along the R&D continuum while also helping to grow our internal pipeline."


PPD employs 50 people in its Meno Park facility. Louise Caudle, a company spokeswman, said that these staffers will have the opportunity to apply for other jobs at the company. PPD said it employs around 5,600 people in 26 countries worldwide.


The restructuring includes a significant agreement with SurroMed, also announced yesterday, in which PPD gave SurroMed an undisclosed cash payment and a range of cancer biomarkers from the Menlo Park facility in exchange for $24 million worth of SurroMed's senior preferred stock.


SurroMed said it intends to use PPD's biomarkers to take a stab at cancer diagnostics, and that it also plans to seek to partner related cancer therapeutic opportunities." The company will also relocate to PPD's erstwhile Menlo Park space. The transactions are expected to close next month.

Additionally, PPD will over the next four years buy biomarker-discovery services from SurroMed, and will become SurroMed's "non-exclusive representative" for sales of additional biomarker-discovery services, the companies said.

"We believe that the collaboration with PPD will allow SurroMed to achieve positive cash flow and sustainability and to expand our leadership position in the field of biomarker discovery," Gordon Ringold, CEO and chairman of SurroMed, said in a separate statement.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.